NVO 6-K
Novo Nordisk A S (NVO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 11, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
|---|
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 11 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Page 2 of 4
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name of the Board member/Executive/Associated<br>Person | David<br>Moore | ||
| 2 | Reason for the<br>notification | |||
| a) | Position/status | Executive<br>Vice President, US Operations | ||
| b) | Initial<br>notification/Amendment | Initial<br>notification | ||
| 3 | Details of the<br>issuer | |||
| a) | Name | Novo<br>Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the<br>transaction(s) | |||
| a) | Description of the financial instrument,<br><br>type of instrument, | Shares | ||
| Identification<br>code | Novo Nordisk<br>B DK0062498333 | |||
| b) | Nature<br>of the transaction | Other<br>transaction (acquisition of shares in accordance with the recruitment package) | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| DKK 0.00 | 18,634 | |||
| d) | Aggregated information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 18,634 shares<br><br>DKK 0.00 | ||
| e) | Date<br>of the transaction | 2025-11-10 | ||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Page 3 of 4
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name of the Board member/Executive/Associated<br>Person | David<br>Moore | ||
| 2 | Reason for the<br>notification | |||
| a) | Position/status | Executive<br>Vice President, US Operations | ||
| b) | Initial<br>notification/Amendment | Initial<br>notification | ||
| 3 | Details of the<br>issuer | |||
| a) | Name | Novo<br>Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the<br>transaction(s) | |||
| a) | Description of the financial instrument,<br><br>type of instrument, | Shares | ||
| Identification<br>code | Novo Nordisk<br>B DK0062498333 | |||
| b) | Nature<br>of the transaction | Sale of shares | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| DKK 297.95 | 8,160 | |||
| d) | Aggregated information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 8,160 shares<br><br>DKK 2,431,301.74 | ||
| e) | Date<br>of the transaction | 2025-11-10 | ||
| f) | Place<br>of the transaction | Nasdaq Copenhagen |
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 4 of 4
Contacts for further information
Media:Ambre James-Brown Liz Skrbkova (US)+45 3079 9289+1 609 917 [email protected]@novonordisk.comInvestors: Jacob Martin Wiborg Rode Sina Meyer+45 3075 5956+45 3079 [email protected]@novonordisk.comChristoffer Sho Togo Tullin Alex Bruce+45 3079 1471+45 3444 [email protected]@novonordisk.comFrederik Taylor Pitter+1 609 613 0568 [email protected]
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 33 / 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 11, 2025 | NOVO NORDISK A/S<br><br>Maziar Mike Doustdar<br><br>Chief Executive Officer |
|---|